Showing results (371-380 of 523) with videos related to

Sort By:
Pageof 53
Autoimmunity Reviews|January 10, 2020
Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in FranceNicolas Noël, Audrey Le Roy, Arnaud Hot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2024
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven MalignanciesFrancesco Facchinetti, Yohann Loriot, Floriane Brayé, et al.
European Journal of Cancer (Oxford, England : 1990)|January 30, 2021
Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapyIthar Gataa, Laura Mezquita, Caroline Rossoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2013
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectivesJulien Mazières, Solange Peters, Benoit Lepage, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2010
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lungNatasha B Leighl, Luis E Raez, Benjamin Besse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2014
Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTEMarie Wislez, Fabrice Barlesi, Benjamin Besse, et al.
European Journal of Cancer (Oxford, England : 1990)|October 28, 2023
Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancerClara Helal, Cédric Pobel, Arnaud Bayle, et al.
ERJ Open Research|February 17, 2018
Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patientsJacques Cadranel, Alexis B Cortot, Hervé Lena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2024
Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological CorrelatesFilippo G Dall'Olio, Wael Zrafi, Veronique Roelants, et al.
Pageof 53